0.00Open0.15Pre Close0 Volume1 Open Interest12.50Strike Price0.00Turnover0.00%IV71.64%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma49.13Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Foghorn Therapeutics Stock Discussion
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet